SVRA stock is taking a big hit in Thursday’s session after Savara Inc (NASDAQ:SVRA) said that Molgradex failed to meet the primary endpoint in a phase 3 study.
Molgradex’s FailureSavara has had a setback in its lead product candidate Molgradex. The company announced that in the latest Phase 3 study into the product, Molgradex failed to hit the desired targets.
The product is meant for the treatment of Autoimmune Alveolar Pulmonary Proteinosis (APAP); however, it did not meet the endpoint targets that had been set, and this is, naturally, a major setback for ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.